Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BalanceD-HF: Balcinrenone/dapagliflozin vs dapagliflozin in heart failure with impaired kidney function
jRCT2031240037Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary composite endpoint. Started Apr 2024; status: active, not recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031240037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240037.